Emmaus Medical, Inc. develops and manufactures pharmaceutical-grade L-glutamine oral powder for the treatment of sickle cell disease.

Emmaus Medical, Inc.

Emmaus Life Sciences, Inc | 8,811 followers on LinkedIn. Improving the lives of people with rare disease. | Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease.  We are initially focusing our product development efforts in Sickle Cell Disease, a genetic disorder.  Our lead product candidate is an oral pharmaceutical grade L-glutamine treatment that demonstrated positive clinical results in our completed Phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia.

CEO at Emmaus Life Sciences / Emmaus Medical

Willis Lee

Rare Disease - Hematology/Oncology, Product Launch, Key Account Management

Traci Evitts

Strategic Account Manager - Rare Disease/ Hematology / Oncology

Richard O'Neal

National Director, Community Engagement Pharmaceuticals Rare Diseases, USA Orphan Drug - Nurse Practitioner Hematology/Oncology

Karen Gant, PhDc APRN FNP-BC

Emmaus Life Sciences, Inc

EMMA

COM:EMMAUSMEDICAL

Emmaus Medical, Inc.